跳转至内容
Merck
  • Evaluation of the usefulness of breast cancer resistance protein (BCRP) knockout mice and BCRP inhibitor-treated monkeys to estimate the clinical impact of BCRP modulation on the pharmacokinetics of BCRP substrates.

Evaluation of the usefulness of breast cancer resistance protein (BCRP) knockout mice and BCRP inhibitor-treated monkeys to estimate the clinical impact of BCRP modulation on the pharmacokinetics of BCRP substrates.

Pharmaceutical research (2014-11-09)
Tsuyoshi Karibe, Rie Hagihara-Nakagomi, Koji Abe, Tomoki Imaoka, Tsuyoshi Mikkaichi, Satoru Yasuda, Masakazu Hirouchi, Nobuaki Watanabe, Noriko Okudaira, Takashi Izumi
摘要

To evaluate whether the impact of functional modulation of the breast cancer resistance protein (BCRP, ABCG2 421C>A) on human pharmacokinetics after oral administration is predictable using Bcrp knockout mice and cynomolgus monkeys pretreated with a BCRP inhibitor, elacridar. The correlation of the changes of the area under the plasma concentration-time curve (AUC) caused by ABCG2 421C>A with those caused by the Bcrp knockout in mice, or BCRP inhibition in monkeys, was investigated using well-known BCRP substrates (rosuvastatin, pitavastatin, fluvastatin, and sulfasalazine). In mice, the bioavailability changes, which corrected the effect of systemic clearance by Bcrp knockout, correlated well with the AUC changes in humans, whereas the correlation was weak when AUC changes were directly compared. In monkeys, the AUC changes pretreated with elacridar resulted in a good estimation of those in humans within approximately 2-fold ranges. This study suggests that pharmacokinetics studies that use the correction of the bioavailability changes in Bcrp knockout mice are effective for estimating clinical AUC changes in ABCG2 421C>A variants for BCRP substrate drugs and those studies in monkeys that use a BCRP inhibitor serve for the assessment of BCRP impact on the gastrointestinal absorption in a non-rodent model.

材料
货号
品牌
产品描述

Sigma-Aldrich
利福平, ≥95% (HPLC), powder or crystals
Sigma-Aldrich
新生霉素 钠盐, ≥90% (HPLC)
Sigma-Aldrich
利福平, suitable for plant cell culture, BioReagent, ≥95% (HPLC), powder or crystals
Sigma-Aldrich
新生霉素 钠, meets USP testing specifications
利福平, European Pharmacopoeia (EP) Reference Standard
Supelco
新生霉素 钠盐, VETRANAL®, analytical standard